181 related articles for article (PubMed ID: 33091789)
1. Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
Qu Y; Zhang C; Ma X; Gao Y; Liu J; Wu L
Bioorg Med Chem; 2020 Dec; 28(24):115821. PubMed ID: 33091789
[TBL] [Abstract][Full Text] [Related]
2. NQO1-selective activated prodrugs of combretastatin A-4: Synthesis and biological evaluation.
Zhang C; Qu Y; Ma X; Li M; Li S; Li Y; Wu L
Bioorg Chem; 2020 Oct; 103():104200. PubMed ID: 32890998
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
Xu S; Yao H; Pei L; Hu M; Li D; Qiu Y; Wang G; Wu L; Yao H; Zhu Z; Xu J
Eur J Med Chem; 2017 May; 132():310-321. PubMed ID: 28395199
[TBL] [Abstract][Full Text] [Related]
4. Transferrin receptor-targeted redox/pH-sensitive podophyllotoxin prodrug micelles for multidrug-resistant breast cancer therapy.
Li Y; Chen M; Yao B; Lu X; Zhang X; He P; Vasilatos SN; Ren X; Bian W; Yao C
J Mater Chem B; 2019 Oct; 7(38):5814-5824. PubMed ID: 31495855
[TBL] [Abstract][Full Text] [Related]
5. ROS-Activated homodimeric podophyllotoxin nanomedicine with self-accelerating drug release for efficient cancer eradication.
Liang B; Zhou D
Drug Deliv; 2021 Dec; 28(1):2361-2372. PubMed ID: 34747277
[TBL] [Abstract][Full Text] [Related]
6. Research advances in NQO1-responsive prodrugs and nanocarriers for cancer treatment.
Yang X; Duan J; Wu L
Future Med Chem; 2022 Mar; 14(5):363-383. PubMed ID: 35102756
[TBL] [Abstract][Full Text] [Related]
7. H
Ou K; Kang Y; Chen L; Zhang X; Chen X; Zheng Y; Wu J; Guan S
Biomater Sci; 2019 May; 7(6):2491-2498. PubMed ID: 30957821
[TBL] [Abstract][Full Text] [Related]
8. 3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.
Jaffar M; Phillips RM; Williams KJ; Mrema I; Cole C; Wind NS; Ward TH; Stratford IJ; Patterson AV
Biochem Pharmacol; 2003 Oct; 66(7):1199-206. PubMed ID: 14505799
[TBL] [Abstract][Full Text] [Related]
9. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
Ma X; Huang X; Moore Z; Huang G; Kilgore JA; Wang Y; Hammer S; Williams NS; Boothman DA; Gao J
J Control Release; 2015 Feb; 200():201-11. PubMed ID: 25542645
[TBL] [Abstract][Full Text] [Related]
10. Intracellular Enzyme-Responsive Profluorophore and Prodrug Nanoparticles for Tumor-Specific Imaging and Precise Chemotherapy.
Pei Q; Lu S; Zhou J; Jiang B; Li C; Xie Z; Jing X
ACS Appl Mater Interfaces; 2021 Dec; 13(50):59708-59719. PubMed ID: 34879654
[TBL] [Abstract][Full Text] [Related]
11. A colon-targeted podophyllotoxin nanoprodrug: synthesis, characterization, and supramolecular hydrogel formation for the drug combination.
Ha W; Zhao XB; Zhao WH; Tang JJ; Shi YP
J Mater Chem B; 2021 Apr; 9(14):3200-3209. PubMed ID: 33885624
[TBL] [Abstract][Full Text] [Related]
12. Enzyme-Instructed Activation of Pro-protein Therapeutics In Vivo.
Chang J; Cai W; Liang C; Tang Q; Chen X; Jiang Y; Mao L; Wang M
J Am Chem Soc; 2019 Nov; 141(45):18136-18141. PubMed ID: 31589435
[TBL] [Abstract][Full Text] [Related]
13. Cancer Targeted Enzymatic Theranostic Prodrug: Precise Diagnosis and Chemotherapy.
Shin WS; Han J; Verwilst P; Kumar R; Kim JH; Kim JS
Bioconjug Chem; 2016 May; 27(5):1419-26. PubMed ID: 27135737
[TBL] [Abstract][Full Text] [Related]
14. A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity.
Zhou H; Lv S; Zhang D; Deng M; Zhang X; Tang Z; Chen X
Acta Biomater; 2018 Jun; 73():388-399. PubMed ID: 29694920
[TBL] [Abstract][Full Text] [Related]
15. Synthetic dimeric-drug phospholipid: a versatile liposomal platform for cancer therapy.
Ling L; Yu H; Ismail M; Zhu Y; Du Y; Qi J
Chem Commun (Camb); 2020 Jul; 56(55):7621-7624. PubMed ID: 32515754
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of NAD(P)H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties.
Zhu H; Lu L; Zhu W; Tan Y; Duan Y; Liu J; Ye W; Zhu Z; Xu J; Xu S
Eur J Med Chem; 2022 Oct; 240():114575. PubMed ID: 35803175
[TBL] [Abstract][Full Text] [Related]
17. GSH-Activated NIR Fluorescent Prodrug for Podophyllotoxin Delivery.
Liu Y; Zhu S; Gu K; Guo Z; Huang X; Wang M; Amin HM; Zhu W; Shi P
ACS Appl Mater Interfaces; 2017 Sep; 9(35):29496-29504. PubMed ID: 28758393
[TBL] [Abstract][Full Text] [Related]
18. Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
Kadela-Tomanek M; Bębenek E; Chrobak E; Marciniec K; Latocha M; Kuśmierz D; Jastrzębska M; Boryczka S
Eur J Med Chem; 2019 Sep; 177():302-315. PubMed ID: 31158746
[TBL] [Abstract][Full Text] [Related]
19. Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system.
Volpato M; Abou-Zeid N; Tanner RW; Glassbrook LT; Taylor J; Stratford I; Loadman PM; Jaffar M; Phillips RM
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3122-30. PubMed ID: 18089707
[TBL] [Abstract][Full Text] [Related]
20. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
Akinboye ES; Rosen MD; Bakare O; Denmeade SR
Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
